Adia Med Files Provisional Patent for Breakthrough Regenerative Medical Protocol

Winter Park, Florida–(Newsfile Corp. – November 12, 2025) – ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced regenerative health solutions, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO) for a novel medical protocol designed to enhance regenerative outcomes.

This Patent Pending innovation represents a significant advancement in ADIA’s mission to deliver cutting-edge, science-backed therapies. The proprietary protocol leverages unique procedural and biological mechanisms previously unexplored in clinical practice, positioning the company at the forefront of regenerative medicine.

“Securing this provisional patent marks a pivotal step in protecting our intellectual property while accelerating development of next-generation health solutions,” Larry Powalisz, CEO of Adia Nutrition. “This filing underscores ADIA’s commitment to innovation that delivers real clinical value.”

The Patent Pending status allows ADIA to advance research, partnerships, and commercialization pathways over the next 12 months while maintaining strategic confidentiality.

ADIA Nutrition plans to provide further updates as development progresses.

Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia’s regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia’s continued mission to expand access to advanced stem cell solutions.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, AdiaLabs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273994